Dual Agonist Combination 3 (Intarcia Therapeutics Inc)

N/A

Report date: 2025/01/26 18:09:15

Base Information

Drug NameDual Agonist Combination 3 (Intarcia Therapeutics Inc)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntarcia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active Companiesi2o Therapeutics Inc
Inactive CompaniesIntarcia Therapeutics Inc
Active IndicationsObesityDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A